Aim Trials — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$69,375	15
2024	Research	$142,383	14
2023	Research	$151,662	14
2022	Research	$122,060	17
2021	Research	$4,650	3
2020	Research	$360	8
2019	Research	$5,714	20

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $240,152 31 payments
Pfizer Inc. $179,644 35 payments
AstraZeneca Pharmaceuticals LP $39,139 5 payments
ACADIA Pharmaceuticals Inc $13,684 5 payments
E.R. Squibb & Sons, L.L.C. $13,657 2 payments
Genzyme Corporation $4,650 3 payments
Sanofi US Services Inc. $3,467 2 payments
Merck Sharp & Dohme Corporation $1,810 8 payments

Studies the money was for Research payments · program years 2019–2025

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $211,866 23 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $178,847 17 payments
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $39,139 5 payments
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder $20,096 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) $13,500 1 payment
Acp-103-070 $11,533 4 payments
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable $4,650 3 payments
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD $3,351 2 payments
Prospective, Observational, Longitudinal Study in Pediatric Patients With Moderate to Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Th $2,702 1 payment
Acp-103-069 $2,151 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.